SII B.1.351

SII B.1.351 is a monovalent COVID-19 vaccine candidate developed to target the SARS-CoV-2 B.1.351 (Beta) variant, which was first identified in South Africa and is characterized by mutations in the spike protein that confer increased transmissibility and partial escape from neutralizing antibodies generated by previous infection or vaccination with earlier strains[3][1][2]. The vaccine is produced by the Serum Institute of India (SII) and utilizes a recombinant protein subunit platform, similar to other vaccines like Novavax's NVX-CoV2373[4]. It contains recombinant spike protein nanoparticles representing the Beta variant, formulated with Matrix-M adjuvant to enhance immune response[4]. The primary indication for this vaccine is prevention of COVID-19 caused by the Beta (B.1.351) variant.

Other names

SII Beta variant vaccine